Thymalin vs Vilon: what the evidence actually shows

Thymalin and Vilon come out of the same Soviet-era research program, and I get asked constantly which one a person should actually pick. Short answer: Thymalin carries the deeper human cohort data and the Russian clinical approval, while Vilon has more distinct human trials across different conditions and is usually the cheaper, easier peptide to source. Neither is a slam dunk against the other. The real answer depends on what you're trying to fix and how much uncertainty you can live with.

Both peptides trace back to Vladimir Khavinson's work at the Military Medical Academy in Leningrad, later continued at the St. Petersburg Institute of Bioregulation and Gerontology. Thymalin is the founding member of that family: a polypeptide complex pulled straight from thymus tissue, lacking a single defined amino acid sequence. Vilon is a later, synthetic descendant, just two amino acids (lysine and glutamate) built to mimic what the tissue extract was doing. That structural difference explains almost every practical gap between them.

Evidence quality: deeper versus wider

Thymalin's headline dataset is a cohort of 266 elderly patients followed for six to eight years, where Thymalin combined with Epithalamin was reported to cut mortality two- to four-fold, in Khavinson and Morozov's 2003 paper. The same cohort turned up again in a 2002 follow-up on geroprotective effects, and a separate 156-patient study found Thymalin normalized lipid metabolism and improved cardiac function in ischemic heart disease patients. More recently, researchers added Thymalin to standard COVID-19 treatment and reported a faster decline in inflammatory markers like IL-6 and CRP, along with lower thrombosis risk, in a 2021 paper from the same research group.

Vilon's human record is thinner per study but spread across more conditions. A 2007 study found improved coagulation and immune markers, plus reduced insulin requirements, in elderly diabetics given Vilon. Separate work looked at diabetic complications and stage-III colorectal cancer survival. None of it is large by Western trial standards, and none of it is randomized or placebo-controlled.

This is all Russian cohort work from one research lineage, with zero RCTs behind either peptide. It's a different tier of evidence than what you'd want before calling something proven. Thymalin's 266-patient, multi-year cohort is the single most substantial piece either peptide has going for it, so if raw evidence depth is your deciding factor, Thymalin wins that comparison outright.

Both peptides share the same underlying mechanism claim worth understanding before you weigh in on either: short peptides derived from tissue supposedly cross into the cell nucleus and interact directly with DNA, nudging gene expression back toward a younger pattern. This has been shown in lab work on HeLa cells and in lymphocytes taken from elderly subjects, where the peptides drove chromatin to decondense and reactivate genes that had gone quiet. It's animal and cell-culture work, so treat it as mechanism support rather than proof either peptide does what the cohort studies claim.

Cost and practical sourcing

Thymalin is a tissue extract, which makes it inherently harder to manufacture and verify than a synthetic dipeptide. That pushes its per-cycle cost above Vilon's in most sourcing I've seen, and it also means a bad batch of Thymalin is harder to spot by eye or by amateur testing than a bad batch of a simple two-amino-acid compound. Vilon, being just lysine and glutamate strung together, is cheaper to synthesize and generally cheaper to buy at a comparable cycle length.

That cost gap matters more than people give it credit for once you're running the Khavinson-style cycle pattern: ten to twenty consecutive days, two to three times a year. Over a full year of cycling, the price difference between the two adds up, and it's a real factor in which one someone actually sticks with.

Side effects and who each one suits

Neither peptide shows a concerning safety signal in the literature. Injection-site irritation and an occasional mild headache early in a cycle are the extent of what's documented, with no serious adverse events reported at standard doses. I've seen this pattern hold across most of the Khavinson family. The real risk with both is the supply chain: this entire peptide family is the most heavily counterfeited category in the space, since Thymalin's extract format is nearly impossible to verify without lab testing, and Vilon's tiny structure makes it cheap for a bad actor to mislabel something else as the real thing.

If you want the deeper, longer-horizon dataset and don't mind paying more for a tissue-extract format, Thymalin is the better fit, and it's also the one that carries an actual clinical approval in Russia, which Vilon doesn't have. If you want a cheaper entry point into this peptide family and value having human data across a wider range of conditions even if each dataset is smaller, Vilon makes more sense. People in the practitioner-camp community I follow often run both across separate cycles rather than picking one permanently, treating them as complementary angles on the same thymic-immune target rather than competitors.

If a thymus-immune peptide with a much stronger Western trial record matters more to you than the Russian-school history, Thymosin alpha-1 is worth reading about before you commit to either Thymalin or Vilon, since it has real human trial data and a far more verifiable supply chain.

Now the part my lawyer makes me say, and he's right to make me say it: the doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.

What people actually run: for Thymalin, a short in-clinic course of small intramuscular injections over the ten-to-twenty day cycle, historically dosed by Russian clinical protocol rather than a home-use standard. For Vilon, subcutaneous dosing has converged around 100 to 200 mcg per day over that same ten-to-twenty day window. Both get repeated two to three times a year, with a long rest in between, and both come as lyophilized powder that needs bacteriostatic water and refrigeration once mixed, good for about 28 days.

For readers building out a broader immune or longevity stack and weighing whether a second thymic peptide adds anything, the Thymalin and Testagen comparison covers that specific pairing question in more depth than I can fit here.